A protocolized maintenance de-escalation permitted daratumumab cessation after ≥2 years plus ≥12 months sustained MRD negativity, with most patients not restarting at data cutoff. Generalizability is ...
A real-world study of fifty multiple myeloma patients found that high-dose melphalan with autologous stem cell ...
Multiple myeloma, an incurable cancer of the bone marrow’s plasma cells, has long defied doctors’ attempts to predict its ...
A phase 1 clinical trial found that an investigational CAR-T therapy can lead to deep and durable responses in people with ...
A short course of ultra-low-dose radiation therapy relieved painful bone lesions from multiple myeloma for most patients in a ...
Analysis showed ~87% of patients treated with TECVAYLI®â–¼ plus daratumumab as early as second line were estimated to have comparable mortality risk to the general population1A separate analysis shows ...
Bonifacio Gurule, a 75-year-old cancer survivor, reflects on his journey of resilience and remission after being diagnosed with multiple myeloma in 2015.
Building disease literacy through MMRF, IMF, and HealthTree enabled informed partnership with myeloma specialists when standard regimens and an initial trial failed. Telehealth during the pandemic ...
In a phase 1 first-in-human trial, BMS-986453 showed a favorable safety profile and high response rates in ...
A short course of ultra-low-dose radiation therapy relieved painful bone lesions from multiple myeloma for most patients in a ...
Arterial thromboembolism affected 2.1% of patients with multiple myeloma, with clinical and genetic risk factors identified.
CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results